{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:42:00Z","timestamp":1761597720197},"reference-count":13,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["YAKUGAKU ZASSHI"],"published-print":{"date-parts":[[2016,6,1]]},"DOI":"10.1248\/yakushi.15-00261","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T22:12:48Z","timestamp":1464732768000},"page":"905-911","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetic and Pharmacodynamic Analyses of Drug-Drug Interactions between Iguratimod and Warfarin"],"prefix":"10.1248","volume":"136","author":[{"given":"Tetsuya","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Research Laboratories, Toyama Chemical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Research Laboratories, Toyama Chemical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Onoda","sequence":"additional","affiliation":[{"name":"Research Laboratories, Toyama Chemical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Research Laboratories, Toyama Chemical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Tanaka K., Yamaguchi T., <i>Nippon Yakurigaku Zasshi<\/i>, <b>140<\/b>, 285-292 (2012).","DOI":"10.1254\/fpj.140.285"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hara M., Abe T., Sugawara S., Mizushima Y., Hoshi K., Irimajiri S., Hashimoto H., Yoshino S., Matsui N., Nobunaga M., <i>Mod. Rheumatol.<\/i>, <b>17<\/b>, 10-16 (2007).","DOI":"10.3109\/s10165-006-0543-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ishiguro N., Yamamoto K., Katayama K., Kondo M., Sumida T., Mimori T., Soen S., Nagai K., Yamaguchi T., Hara M.; Iguratimod-Clinical Study Group, <i>Mod. Rheumatol.<\/i>, <b>23<\/b>, 430-439 (2013).","DOI":"10.3109\/s10165-012-0724-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Tanaka K., Yamaguchi T., Hara M., <i>Expert Rev. Clin. Immunol.<\/i>, <b>11<\/b>, 565-573 (2015).","DOI":"10.1586\/1744666X.2015.1027151"},{"key":"5","unstructured":"5) Ministry of Health, Lobour, and Welfare, &ldquo;Careram<sup>&reg;<\/sup> Tablets 25 mg; KOLBET<sup>&reg;<\/sup> Tablets 25 mg (Iguratimod)&mdash;Risk of severe haemorrhages by a suspected interaction with warfarin,&rdquo; Blue letter, May 2013."},{"key":"6","unstructured":"6) Taisho Toyama Pharmaceutical Co., Ltd., Interview Form, KOLBET<sup>&reg;<\/sup> Tablets 25 mg, 6th ed., 2013."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kurata M., Iidaka T., Yamasaki N., Sasayama Y., Hamada Y., <i>Exp. Anim.<\/i>, <b>54<\/b>, 189-192 (2005).","DOI":"10.1538\/expanim.54.189"},{"key":"8","unstructured":"8) Pfizer Inc., Interview Form, Diflucan intravenous solution 50 mg, 100 mg, 200 mg, 8th ed., 2013."},{"key":"9","unstructured":"9) The following rat PK parameters were obtained on a six-month repeated oral dose toxicity study of IGU in rats: C<sub>max<\/sub>, AUC<sub>0-24 h<\/sub> and t<sub>max<\/sub> of IGU after administration of 30 mg\/kg were 31.2 &mu;g\/mL, 435.5 &mu;g&middot;h\/mL and 4 h, respectively."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ito K., Chiba K., Horikawa M., Ishigami M., Mizuno N., Aoki J., Gotoh Y., Iwatsubo T., Kanamitsu S., Kato M., Kawahara I., Niinuma K., Nishino A., Sato N., Tsukamoto Y., Ueda K., Itoh T., Sugiyama Y., <i>AAPS PharmSci.<\/i>, <b>4<\/b>, 53-60 (2002).","DOI":"10.1208\/ps040425"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Uchida S., Tanaka S., Namiki N., <i>Biopharm. Drug Dispos.<\/i>, <b>35<\/b>, 228-236 (2014).","DOI":"10.1002\/bdd.1888"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Szutowski M. M., &#x141;ukasik M., Wawer Z. T., Chrobak K., Michalska M., Borzecka K., Brzezi&#x144;ski J., <i>J. Appl. Toxicol.<\/i>, <b>22<\/b>, 327-332 (2002).","DOI":"10.1002\/jat.867"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yamaori S., Takami K., Shiozawa A., Sakuyama K., Matsuzawa N., Ohmori S., <i>Biol. Pharm. Bull.<\/i>, <b>38<\/b>, 441-447 (2015).","DOI":"10.1248\/bpb.b14-00711"}],"container-title":["YAKUGAKU ZASSHI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/136\/6\/136_15-00261\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T11:55:09Z","timestamp":1536407709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/136\/6\/136_15-00261\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1248\/yakushi.15-00261","relation":{},"ISSN":["0031-6903","1347-5231"],"issn-type":[{"value":"0031-6903","type":"print"},{"value":"1347-5231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,1]]}}}